Angela C. Wagoner
Angela C. Wagoner has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Amy Rasley
Physical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, CA 94551, USA
1 shared publication Angel Hsu
Pre-Pivotal Drug Product Technologies, Process Development, Operations
1 shared publication- Benjamin Lew
University of Illinois at Urbana-Champaign, Department of Electrical and Computer Engineering, Urbana, Illinois, United States
1 shared publication - Brendan R. Amer
Pre-Pivotal Drug Product Technologies, Process Development, Operations
1 shared publication Deirdre Murphy Piedmonte
Pre-Pivotal Drug Product Technologies, Process Development, Operations
1 shared publication- Delia F. Tifrea
Department of Pathology and Laboratory Medicine, Medical Sciences I, Room D440, University of California, Irvine, Irvine, CA 92697-4800, USA
1 shared publication
Latest Publications
- Open Access
- 7 July 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (8) , 4587-4596
Surface Plasmon Resonance Based Binding Characterization for Screening RNA-Loaded Lipid Nanoparticles (LNPs): Exploring Species Cross-Reactivity in LNP–Apolipoprotein E Interactions
Lipid nanoparticles (LNPs) are an essential delivery platform for nucleic acid payloads that are susceptible to degradation or elimination. Upon administration, a biomolecular corona composed of serum proteins forms around the LNP surface, which is crucial for tissue targeting and biodistribution. One essential protein that drives the distribution of LNPs is apolipoprotein E (ApoE). In this work, we used ApoE as a model protein to probe LNP-protein interactions utilizing a surface plasmon resonance (SPR) interaction assay comparable to the conventional quartz crystal microbalance with dissipation (QCM-D) assay. We employed two LNP formulations with or without payload and various ApoE homologs to establish the SPR method as an in vitro tool to screen LNP formulations and explore species cross-reactivity in LNP-protein interactions. Two binding models were applied to capture the difference in binding behaviors of different ApoE homologs in terms of relative binding response and association kinetics.
- 7 July 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (8) , 4587-4596
Open AccessSurface Plasmon Resonance Based Binding Characterization for Screening RNA-Loaded Lipid Nanoparticles (LNPs): Exploring Species Cross-Reactivity in LNP–Apolipoprotein E Interactions
Lipid nanoparticles (LNPs) are an essential delivery platform for nucleic acid payloads that are susceptible to degradation or elimination. Upon administration, a biomolecular corona composed of serum proteins forms around the LNP surface, which is crucial for tissue targeting and biodistribution. One essential protein that drives the distribution of LNPs is apolipoprotein E (ApoE). In this work, we used ApoE as a model protein to probe LNP-protein interactions utilizing a surface plasmon resonance (SPR) interaction assay comparable to the conventional quartz crystal microbalance with dissipation (QCM-D) assay. We employed two LNP formulations with or without payload and various ApoE homologs to establish the SPR method as an in vitro tool to screen LNP formulations and explore species cross-reactivity in LNP-protein interactions. Two binding models were applied to capture the difference in binding behaviors of different ApoE homologs in terms of relative binding response and association kinetics.
- Open Access
Induction of Protection in Mice against a Chlamydia muridarum Respiratory Challenge by a Vaccine Formulated with the Major Outer Membrane Protein in Nanolipoprotein Particles
Chlamydia trachomatis is a sexually transmitted bacterium that infects over 130 million individuals worldwide annually. To implement a vaccine, we developed a cell-free co-translational system to express the Chlamydia muridarum major outer membrane protein (MOMP). This approach uses a nanolipoprotein particles (tNLP) made from ApoA1 protein, amphiphilic telodendrimer and lipids that self-assemble to form 10–25 nm discs. These tNLP provide a protein-encapsulated lipid support to solubilize and fold membrane proteins. The cell-free system co-translated MOMP and ApoA1 in the presence of telodendrimer mixed with lipids. The MOMP-tNLP complex was amenable to CpG and FSL-1 adjuvant addition. To investigate the ability of MOMP-tNLP+CpG+FSL-1 to induce protection against an intranasal (i.n.) C. muridarum challenge, female mice were vaccinated intramuscularly (i.m.) or i.n. and i.m. simultaneously 4 weeks apart. Following vaccination with MOMP-tNLP+CpG+FSL-1, mice mounted significant humoral and cell-mediated immune responses. Following the i.n. challenge, mice vaccinated with MOMP-tNLP+CpG+FSL-1 i.n. + i.m. group were protected as determined by the percentage change in body weight and by the number of C. muridarum inclusion forming units (IFU) recovered from the lungs. To our knowledge, this is the first time a MOMP-based vaccine formulated in tNLP has been shown to protect against C. muridarum.
Open AccessInduction of Protection in Mice against a Chlamydia muridarum Respiratory Challenge by a Vaccine Formulated with the Major Outer Membrane Protein in Nanolipoprotein Particles
Chlamydia trachomatis is a sexually transmitted bacterium that infects over 130 million individuals worldwide annually. To implement a vaccine, we developed a cell-free co-translational system to express the Chlamydia muridarum major outer membrane protein (MOMP). This approach uses a nanolipoprotein particles (tNLP) made from ApoA1 protein, amphiphilic telodendrimer and lipids that self-assemble to form 10–25 nm discs. These tNLP provide a protein-encapsulated lipid support to solubilize and fold membrane proteins. The cell-free system co-translated MOMP and ApoA1 in the presence of telodendrimer mixed with lipids. The MOMP-tNLP complex was amenable to CpG and FSL-1 adjuvant addition. To investigate the ability of MOMP-tNLP+CpG+FSL-1 to induce protection against an intranasal (i.n.) C. muridarum challenge, female mice were vaccinated intramuscularly (i.m.) or i.n. and i.m. simultaneously 4 weeks apart. Following vaccination with MOMP-tNLP+CpG+FSL-1, mice mounted significant humoral and cell-mediated immune responses. Following the i.n. challenge, mice vaccinated with MOMP-tNLP+CpG+FSL-1 i.n. + i.m. group were protected as determined by the percentage change in body weight and by the number of C. muridarum inclusion forming units (IFU) recovered from the lungs. To our knowledge, this is the first time a MOMP-based vaccine formulated in tNLP has been shown to protect against C. muridarum.